Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CCND1 Positive”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Testing effectiveness (Phase 2)Study completedNCT00835419
What this trial is testing

Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression

Who this might be right for
Melanoma
Piramal Enterprises Limited 12
Testing effectiveness (Phase 2)WithdrawnNCT03232307
What this trial is testing

Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma

Who this might be right for
CCND1 PositiveCD20-Positive Neoplastic Cells PresentMantle Cell Lymphoma
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT03872180
What this trial is testing

Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Who this might be right for
CCND1 PositiveMantle Cell Lymphomat(11;14) Positive
Emory University 23
Large-scale testing (Phase 3)Study completedNCT02785939
What this trial is testing

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Who this might be right for
CCND1 Gene AmplificationCCND2 Gene AmplificationCCND3 Gene Amplification+3 more
SWOG Cancer Research Network 53
Testing effectiveness (Phase 2)Active Not RecruitingNCT01880567
What this trial is testing

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

Who this might be right for
CCND1 PositiveCCND2 PositiveCCND3 Positive+4 more
M.D. Anderson Cancer Center 113
Testing effectiveness (Phase 2)Active Not RecruitingNCT03946878
What this trial is testing

Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Who this might be right for
Blastoid Variant Mantle Cell LymphomaCCND1 Protein OverexpressionCD20 Positive+6 more
M.D. Anderson Cancer Center 32